Enabling DCIS subtyping: leveraging foundation models for robust grading and molecular biomarker scoring

npj Breast Cancer · Published 2026-05-06 · DOI 10.1038/s41523-026-00957-6

Authors being retrieved — see the publisher record. https://doi.org/10.1038/s41523-026-00957-6

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Risk factors and metastatic sites in HER2-positive breast cancer with pathological complete response · npj Breast Cancer · 2026 · Same journal
Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression · npj Breast Cancer · 2026 · Same journal
Clinical significance of residual microcalcifications after neoadjuvant chemotherapy: MRI response and the subtypes · npj Breast Cancer · 2026 · Same journal
Imlunestrant with or without abemaciclib in advanced breast cancer: safety analyses from the EMBER-3 trial · npj Breast Cancer · 2026 · Same journal
Facing death: the last drawings of a woman with breast cancer at the end of life · npj Breast Cancer · 2026 · Same journal
Impact of neoadjuvant chemotherapy on local breast microbiota and macrophages in ER-positive breast cancer with links to treatment response · npj Breast Cancer · 2026 · Same journal
PCSK9 rs562556 variant and survival in BRCA1 mutation carriers and mutation-negative familial breast cancer · npj Breast Cancer · 2026 · Same journal
Patient-reported outcomes as early indicators of recurrence, disease progression, and survival via machine learning in breast cancer · npj Breast Cancer · 2026 · Same journal
External validation of four breast cancer risk prediction models for personalized screening in a prospective Dutch screening cohort · npj Breast Cancer · 2026 · Same journal
Predicting early-stage breast cancer disease-free survival and adjuvant therapy benefit from multimodal information using deep learning · npj Breast Cancer · 2026 · Same journal